PAOG Targets International Segment Of $5 Billion CBD Nutraceutical Market
13 5월 2021 - 10:29PM
InvestorsHub NewsWire
Sandusky, OH -- May 13, 2021 -- InvestorsHub NewsWire -- PAO
Group, Inc. (USOTC:
PAOG) today revealed it will include foreign sales in the
planned Q4 launch of its three CBD Nutraceutical Products.
The 2020 CBD
Nutraceuticals Market had an estimated value of $5.2 Billion
and it is expected to reach $16.4 Billion by 2027.
That market value represents global sales. PAOG management is
targeting specific international segments to be included in its Q4
sales launch. PAOG management anticipates a lower market
entry expense in the targeted international segments. PAOG
management also anticipates the international segments to likely
contribute a major portion of its overall CBD Nutraceutical
sales.
Last week, PAOG released a preview of the company’s plan to launch
a CBD Nutraceuticals line of products. PAOG’s CBD
Nutraceuticals are expected to generate revenue this year, in 2021,
while the company continues with its long-term CBD pharmaceutical
developments.
PAOG is working on the development of a CBD pharmaceutical product
under the name RespRx, for the treatment of Chronic Obstructive
Pulmonary Disorder (COPD) derived from a patented cannabis
extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND
APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE
CANNABIS PLANT."
The first CBD Nutraceutical under development will sell under the
name CBD RELAX-RX targeting the anxiety and depression treatment
market anticipated to reach a value of $18
billion by 2025.
The second CBD Nutraceutical under development will be derived from
PAOG’s ongoing COPD research targeting the COPD treatment market
separately from the pharmaceutical market also targeting COPD
treatment.
The third CBD Nutraceutical is being developed in partnership with
the EVERx CBD Sports Water Brand owned by Puration, Inc.
(USOTC:
PURA) and will target the sports nutrition market.
PAOG plans to develop and distribute its CBD nutraceuticals with
Alkame Holdings, Inc. (OTC
Pink: ALKM) as a copacker and North American Cannabis Holdings,
Inc. (OTC
Pink: USMJ) as a distributor.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release
may contain forward-looking information within the meaning of Rule
175 under the Securities Act of 1933 and Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe harbor
created by those rules. All statements, other than statements of
fact, included in this release, including, without limitation,
statements regarding potential future plans and objectives of the
company are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Technical complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
PAO (PK) (USOTC:PAOG)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
PAO (PK) (USOTC:PAOG)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
PAO Group Inc (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More PAO Group Inc (PK) News Articles